Analysts Set Aura Biosciences, Inc. (NASDAQ:AURA) PT at $23.00

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have been given a consensus recommendation of “Buy” by the seven ratings firms that are presently covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $23.00.

Separately, Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st.

Insider Activity

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the sale, the insider now directly owns 304,692 shares of the company’s stock, valued at $2,336,987.64. This represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 23,045 shares of company stock worth $177,242 over the last quarter. Corporate insiders own 5.40% of the company’s stock.

Institutional Trading of Aura Biosciences

Hedge funds have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. lifted its position in Aura Biosciences by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after buying an additional 3,612 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Aura Biosciences by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock worth $8,327,000 after acquiring an additional 3,972 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Aura Biosciences by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 27,623 shares of the company’s stock worth $227,000 after acquiring an additional 5,930 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Aura Biosciences during the fourth quarter worth $50,000. Finally, Bank of America Corp DE raised its holdings in shares of Aura Biosciences by 20.5% during the fourth quarter. Bank of America Corp DE now owns 51,286 shares of the company’s stock worth $422,000 after acquiring an additional 8,709 shares in the last quarter. 96.75% of the stock is owned by hedge funds and other institutional investors.

Aura Biosciences Stock Up 0.9 %

Shares of Aura Biosciences stock opened at $7.49 on Monday. The firm has a market cap of $374.13 million, a price-to-earnings ratio of -4.33 and a beta of 0.30. The business has a fifty day simple moving average of $7.67 and a 200-day simple moving average of $8.66. Aura Biosciences has a fifty-two week low of $6.63 and a fifty-two week high of $12.38.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.